-
1 Comment
BioArctic AB (publ) is currently in a long term uptrend where the price is trading 53.9% above its 200 day moving average.
From a valuation standpoint, the stock is 90.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 129.1.
BioArctic AB (publ)'s total revenue sank by 68.4% to $8M since the same quarter in the previous year.
Its net income has increased by 22.8% to $-13M since the same quarter in the previous year.
Finally, its free cash flow grew by 36.9% to $-34M since the same quarter in the previous year.
Based on the above factors, BioArctic AB (publ) gets an overall score of 4/5.
Exchange | F |
---|---|
CurrencyCode | EUR |
ISIN | SE0010323311 |
Sector | Healthcare |
Industry | Biotechnology |
Market Cap | 1B |
---|---|
PE Ratio | 16.85 |
Target Price | None |
Beta | -0.71 |
Dividend Yield | None |
BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of innovative biological drugs, such as antibodies that address high unmet medical needs. The company's therapeutic areas encompass neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and other CNS diseases. In addition, it owns a technology platform, which develops a range of therapeutic monoclonal antibodies. Additionally, the company is developing lecanemab, which is in phase 3 clinical trials; Lecanemab that is in back-up phase 3 clinical trials; Exidavnemab, which is in phase 2 clinical trials; Lecanemab, BAN2803, and BAN2802 that are in preclinical trials; and BAN1503, PD-BT2238, ND-BT3814, and GD-BT6822, which are in discovery stage. It has research collaboration agreements with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for B9A.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025